Adding pembrolizumab to standard concurrent chemoradiotherapy significantly improves overall survival in patients with high-risk, locally advanced cervical cancer. In a phase 3 trial presented at ESMO, the trial showed a statistically significant improvement in overall survival with pembrolizumab plus CCRT vs placebo. The trial included 1060 patients with high-risk cervical cancer, and the safety profile was manageable. The results suggest pembrolizumab in combination with chemoradiation as the new standard of care. Further investigation is needed to understand the effects on recurrence, long-term survival, and optimal treatment duration. The study was well-designed and included a defined high-risk population.
Source link
Pembrolizumab Plus CCRT Improves Overall Survival
